TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04992728

Intervention type: OTHER
Intervention: Restricted Spectrum Magnetic Resonance Imagining
Description: Restriction Spectrum Magnetic Resonance Imaging (RS-MRI), which uses magnetism instead of x-rays to build up a picture of the inside of the body. The scan is completely painless but can be rather noisy and requires the patient to lie very still inside the center of a large, doughnut-shaped magnet for approximately 30-60 minutes complete the imaging.
Study: NCT05124184

Intervention type: DEVICE
Intervention: GORE® PROPATEN® Vascular Graft
Description: Patients that have had treatment with GORE® PROPATEN® Vascular Graft

Intervention type: DEVICE
Intervention: GORE-TEX® Vascular Grafts
Description: Patients that have had treatment with GORE-TEX® Vascular Grafts

Intervention type: DEVICE
Intervention: GORE-TEX® Vascular Grafts
Description: Patients that have had treatment with GORE-TEX® Vascular Grafts
Study: NCT04926974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Vision Rehabilitation
Description: Smart phone App

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Vision Rehabilitation
Description: Smart phone App

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Vision Rehabilitation
Description: Smart phone App
Study: NCT06445868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sedentary behaviour intervention
Description: COM-B-based development of specific sedentary behavioral interventions to reduce sedentary time, promote healthy activity, and improve quality of life in older stroke patients
Study: NCT06151171

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CoQ10
Description: Participants will be randomly and blindly assigned to receive a single dose (200 mg) of one of the preparations (treatments).~Fasting blood samples are taken at baseline (t=0) or pre-dose for CoQ10 baseline determination.~Participants receive treatment at time zero with a glass of water (\~ 125 mL), along with a standardized breakfast-provided immediately after the dose.~Capsules are administered as a single oral dose, with a wash-out period of at least 3-4 weeks between the two Coenzyme Q10 test products.~Capillary blood samples are collected at time points 0, 0.5, 1, 2, 3, 4,5, 6, 8, 10, 12, 24, 48- and 72-hours post-dose. A standardized lunch is provided after the 4hr blood sample, as well as a standardized dinner after the 8-h sample. Identical meals are served to all participants on each test day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CoQ10
Description: Participants will be randomly and blindly assigned to receive a single dose (200 mg) of one of the preparations (treatments).~Fasting blood samples are taken at baseline (t=0) or pre-dose for CoQ10 baseline determination.~Participants receive treatment at time zero with a glass of water (\~ 125 mL), along with a standardized breakfast-provided immediately after the dose.~Capsules are administered as a single oral dose, with a wash-out period of at least 3-4 weeks between the two Coenzyme Q10 test products.~Capillary blood samples are collected at time points 0, 0.5, 1, 2, 3, 4,5, 6, 8, 10, 12, 24, 48- and 72-hours post-dose. A standardized lunch is provided after the 4hr blood sample, as well as a standardized dinner after the 8-h sample. Identical meals are served to all participants on each test day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CoQ10
Description: Participants will be randomly and blindly assigned to receive a single dose (200 mg) of one of the preparations (treatments).~Fasting blood samples are taken at baseline (t=0) or pre-dose for CoQ10 baseline determination.~Participants receive treatment at time zero with a glass of water (\~ 125 mL), along with a standardized breakfast-provided immediately after the dose.~Capsules are administered as a single oral dose, with a wash-out period of at least 3-4 weeks between the two Coenzyme Q10 test products.~Capillary blood samples are collected at time points 0, 0.5, 1, 2, 3, 4,5, 6, 8, 10, 12, 24, 48- and 72-hours post-dose. A standardized lunch is provided after the 4hr blood sample, as well as a standardized dinner after the 8-h sample. Identical meals are served to all participants on each test day.
Study: NCT03698006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% Injectable Solution
Description: Tibial nerve block with 10ml of Ropivacaine 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2% Injectable Solution
Description: Infiltration with 25ml of Ropivacaine 0.2% in the posterior knee capsule
Study: NCT01104844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Full Dose Strength
Description: Acetaminophen + ibuprofen, 2 tablets every 6 hours, with food for 24 hours (i.e a total of 4 x 1000/300 mg doses of study drug comprising of 8 tablets)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quarter dose strength
Description: Investigational drug quarter dose strength (acetaminophen 125mg + ibuprofen 37.5mg) i.e. 2 tablets equating to 1/4 the dose in the standard investigational drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Half dose strength
Description: Investigational drug half dose strength (acetaminophen 250mg + ibuprofen 75mg) i.e. 2 tablets equating to 1/2 the dose in the standard investigational drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen standard dose
Description: Acetaminophen standard dose 500mg i.e. 2 tablets equating to the same acetaminophen dose as in the standard investigational drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen low dose
Description: Ibuprofen low dose 150mg tablet i.e. 2 tablets equating to the same ibuprofen dose as in the standard investigational product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen high dose
Description: Ibuprofen high dose 300mg i.e. 2 tablet equating to twice the ibuprofen dose as in the standard investigational drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo tablets
Study: NCT05944796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diathermy
Description: The patients belonging to the experimental group will undergo 10 diathermy sessions. The control group will have the same sessions but in athermy (placebo)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients belonging to the placebo group will undergo 10 placebo sessions (athermya)
Study: NCT05409391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin Titration System
Description: A noval insulin titration system, which is based on deep learning
Study: NCT05939167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell
Description: Mesenchymal stem cell dose is 0.75-1.0×10\*6/kg and is transplanted by intravenous infusion. For the mesenchymal stem cell standard treatment group, the cells are used for three times(at week 0, 2,4 after recruitment) and the mesenchymal stem cell enhanced treatment group, the cells are used for six times(at week 0, 2,4,24,26,28 after recruitment).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell
Description: Mesenchymal stem cell dose is 0.75-1.0×10\*6/kg and is transplanted by intravenous infusion. For the mesenchymal stem cell standard treatment group, the cells are used for three times(at week 0, 2,4 after recruitment) and the mesenchymal stem cell enhanced treatment group, the cells are used for six times(at week 0, 2,4,24,26,28 after recruitment).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: saline is used as placebo in the placebo comparator group
Study: NCT04799990

Intervention type: DRUG
Intervention: Risankizumab
Description: Subcutaneous Injection

Intervention type: BIOLOGICAL
Intervention: Comparator 1
Description: Subcutaneous or Intravenous Injection

Intervention type: DRUG
Intervention: Comparator 2
Description: Oral, Opthalmic, Subcutaneous or Intravenous Injection
Study: NCT06265025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM103 (Part A)
Description: dose escalation of GM103 as monotherapy, conducted in 12-24 patients. Part A will include a screening period of up to 28 days, a dose limiting toxicity (DLT) evaluation period of the first 2 cycles, and a treatment period from cycles 3-12 (each cycle will consist of 14 days \[2 weeks\]).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM103 (Part B)
Description: dose expansion study of GM103 as monotherapy, conducted in up to 40 patients (a minimum of 20 patients per target disease \[HNC, CRC\]). Part B of the study will include a screening period of up to 28 days, and 1 to a maximum of 12 treatment cycles (each cycle will consist of 14 days \[2 weeks\]).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM103 and Pembrolizumab (Part C)
Description: dose-escalation and dose-expansion of GM103 in combination with pembrolizumab, conducted in approximately 61 patients. Part C of the study will include a screening period of up to 28 days, a safety run-in period of 2 cycles (it consists of 2 cohorts and the first 1 cycle for the DLT assessment period of each cohort is included, each cycle will consist of 21 days \[3 weeks\]), and a dose expansion period from cycle 3 to a maximum of 12 treatment cycles (of 21 days \[3 weeks\]).
Study: NCT04816812

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise intervention
Description: A 12-week aerobic exercise program tailored to the individual patients by physiotherapists using the principles of Frequency, Intensity, Time, and, Type (FITT) aiming to increase or maintain the physical activity level to a weekly moderate activity level. This includes two supervised exercise sessions of 60 minutes per week, combined with one weekly home training session. The type of exercise is planned by a physiotherapist to fit each patient during sessions. We monitor the intervention by training diaries including frequency, intensity, time, and type of exercise (FITT) and the verbal BORG 15-point scale and heart rate monitors. We will also monitor the overall seven days' physical activity level by accelerometry using the AX3 device from the company Axivity at weeks 0 and 12.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle - online lesson intervention
Description: The investigators offer one online lesson of 15-25 minutes on lifestyle guidance including general advice on healthy living.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle - online lesson intervention
Description: The investigators offer one online lesson of 15-25 minutes on lifestyle guidance including general advice on healthy living.
Study: NCT05453643

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sleep deprivation patterns
Description: Sleep deprivation patterns 1 (SDP1) ; total sleep deprivation for 24 hours followed by early morning sleep and an extended 17 hours wakefulness. Sleep deprivation patterns 2 (SDP2) : Sleep interrupted by two half-hour awakenings
Study: NCT04834531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zhuli capsule
Description: This capsule is made from the exact of Phyllostachys glauca McClure or Phyllostachysnuda McClure, which has the expectorant effects. It is oral used,2 capsules for once, three times a day, for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsule is filled with amylodextrin made with food colour and flavor，with the similar appearance, smell and flavor with Zhuli Capsule. It is oral used, 2 capsules for once, three times a day, for 7 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard medical treatment
Description: Standard medical treatment will be given according to the recent guidelines with the evaluation of the clinicians, include:~1. if the patient with AECOPD, he or she will be given with oxygen therapy, bronchodilators, glucocorticoid or antibacterial drugs;~2. if the patient with AECB, he or she will be given with antibacterial drugs or anti-asthmatic drugs for asthma attacks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard medical treatment
Description: Standard medical treatment will be given according to the recent guidelines with the evaluation of the clinicians, include:~1. if the patient with AECOPD, he or she will be given with oxygen therapy, bronchodilators, glucocorticoid or antibacterial drugs;~2. if the patient with AECB, he or she will be given with antibacterial drugs or anti-asthmatic drugs for asthma attacks.
Study: NCT05090839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly Emotional Disclosure (WED)
Description: Online writing session with each session lasting approximately 30 minutes. Participants will be instructed to write about either a major traumatic life experience or what the participant did the previous day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weekly Emotional Disclosure (WED)
Description: Online writing session with each session lasting approximately 30 minutes. Participants will be instructed to write about either a major traumatic life experience or what the participant did the previous day.
Study: NCT04977180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardioprotection
Description: Preventive beta blocker (metoprolol or carvedilol) and an ACE inhibitor (lisinopril)
Study: NCT05196945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vonoprazan fumarate + amoxicillin
Description: vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin 750mg/ time, 4 times/day, oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole +Amoxicillin+Clarithromycin+Bismuth potassium citrate
Description: Esomeprazole 20mg/ time, 2 times/day, oral Amoxicillin 1g/ time, 2 times/day, oral Clarithromycin 0.5g/ time, 2 times/day, oral Bismuth potassium citrate 220mg/ time, twice a day, orally
Study: NCT04882891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actimyo
Description: Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
Study: NCT05075356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The intelligent total body scanner (iToBoS)
Description: The intelligent total body scanner (iToBoS) device will be an AI diagnostic platform for early detection for melanoma, which includes a novel total-body high-resolution scanner and a Computer Aided Diagnostics (CAD) tool. The prototype iToBoS imaging device used in this study, will not have the integrated CAD system.~The device consists of a horizontal bed on which the participant would lie on. The bed will slide under a series of 5 arc shaped rails that have a total of 15 vision units mounted on rails (3 vision units per arc). The vision units incorporate high-resolution cameras and LED lighting system. When imaging is initiated by an operator, the vision units systematically move along the arch rails taking numerous images capturing majority of the skin surface. The imaging process will take approx. 10 minutes.~Purpose built software will be used to stitch images together to create a body avatar on which skin lesions can be viewed and monitored with.
Study: NCT04522674

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous platelet rich plasma
Description: 0.5 mL autologous platelet rich plasma into a symptomatic osteoarthritic lumbar facet to treat back pain caused by lumbar facet syndrome
Study: NCT05336071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS068 injection
Description: Group A subjects were injected formulation T and formulation R of INS068 injection at Day1 and Day8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS068 injection
Description: Group B subjects were injected formulation R and formulation T of INS068 injection at Day1 and Day8.
Study: NCT04947488

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bioarginina C
Description: Dietary supplement vials

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Bioarginina C
Description: Dietary supplement vials
Study: NCT06187376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herbal Medicine (CHM) supplement
Description: Dropper of tincture by mouth for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tincture.
Study: NCT05355142

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PM+
Description: 1 Brief introduction to PM+ \& NDA (5 min) Assessment-based review with PSYCHOLOPS (psychopomps psychology ) assessment (10 min) What is PM+ (20 minutes) Understanding Adversity (30 minutes) Stress Management (20 minutes) Closing the meeting (5 minutes)~2 General Review (5 min) Issue management (70 minutes) Stress management (10 minutes) Closing the meeting (5 minutes)~3 General Review (5 minutes) Problem Management (35 minutes) Take action and be consistent (35 minutes) Stress management (10 minutes) Closing the meeting (5 minutes)~4 General Review (5 minutes) Issue Management (20 minutes) Take action and be persistent (20 minutes) Strengthening Social Support (30 minutes) Stress management (10 minutes) Closing the meeting (5 minutes)~5 General Review (20 minutes) Staying Healthy (30 minutes) Imagining how to help someone (20 minutes) Looking ahead (15 minutes) Closing the de-briefing (5 minutes)
Study: NCT05815303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: 10mg/kg iv on day 1, every 21 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m2 iv on day 1, every 21 day

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Oxaliplatin
Description: 130mg/m2 iv on day 1, every 21 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m2 po bid on day 1 to 14, every 21 day

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Capecitabine
Description: 1000mg/m2 po bid on day 1 to 14, every 21 day
Study: NCT05534932

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Patient Monitoring
Description: Subjects in this group will receive RPM therapy through the University of Chicago Heart Failure program. This therapy consist of a bluetooth tablet, blood pressure cuff and a health scale for subjects to bring home and take thier measurements on a daily bases up to their 3 month clinic visit. This data will then be transmitted to EPIC where the study team will retrieve the data.
Study: NCT06500091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2916 injection + doxorubicin hydrochloride for injection
Description: TQB2916 is a humanized immune gamma globulins 2 (IgG2) monoclonal antibody targeting CD40.~The mechanism of action of doxorubicin is mainly to destroy the DNA structure of tumor cells, thereby killing malignant tumors. It interferes with the DNA synthesis process of cancer cells by targeting DNA and inhibiting enzymes in DNA replication and repair. In addition, doxorubicin can also trigger cross-link breaks in DNA, leading to apoptosis of cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2916 injection+penpulimab injection
Description: TQB2916 is a humanized IgG2 monoclonal antibody targeting CD40. Penpulimab injection is a programmed cell death protein 1 (PD-1) immune checkpoint inhibitor.
Study: NCT05785312

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Online EMDR Therapy System
Description: Online EMDR Therapy System will be delivered through online computer system that will be specifically designed for delivering EMDR therapy online

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face to Face Eye Movement Desensitization & Reprocessing Therapy
Description: The Face to Face Eye Movement Desensitization \& Reprocessing Therapy will be delivered in person inside clinician's room by following standard EMDR therapy protocol
Study: NCT05133635

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Patients with the clinical and laboratory diagnosis of cytokine storm will receive methylprednisolone 250 mg for 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Patients with the clinical and laboratory diagnosis of cytokine storm will receive tocilizumab 400-800 mg for one time.
Study: NCT05312034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation of the predictive model for an antimicrobial management program
Description: Firstly it will be used the predictive model as a simulation tool to educate physicians. For three months, physicians will use the model to understand the main factors associated with Gram-positive infection. They will test the model using real-case data previously collected at the hospitals. The model will provide them information such as the probability of that patient having a Gram-positive infection and the proportion of infected patients in that ICU and hospital.~This model will be embedded in an app and a web page to provide real-time guidance on the predicted probability of infection due to Gram-positive agents.~The intervention will be implemented in two selected hospitals, aiming at monthly decreasing the use of broad-spectrum antibiotics while maintaining or reducing the ICU standardized mortality ratio and the standardized resource use.
Study: NCT06221163

Intervention type: OTHER
Intervention: collection of biographical and sociological data
Description: collection of biographical and sociological data. Conducting non-directive interviews (life stories) with transgender patients consulting the Reproductive Medicine Department and their volunteer relatives. Patients are given a 'flyer' at the time of their consultation on which the interviewer's contact details are given. They are free to contact the interviewer to find out when and where an interview might take place (outside hospital).
Study: NCT05086471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NaviCam SB
Description: Subjects swallow two types of SB capsules approximately 40 minutes apart in a randomized order. During the capsule endoscopy, the doctor can view the small bowel images taken by the capsules in real time.

Intervention type: DEVICE
Group type: OTHER
Intervention: PillCam SB3
Description: Subjects swallow two types of SB capsules approximately 40 minutes apart in a randomized order. During the capsule endoscopy, the doctor can view the small bowel images taken by the capsules in real time.
Study: NCT05124184

Intervention type: DEVICE
Intervention: GORE-TEX® Vascular Grafts
Description: Patients that have had treatment with GORE-TEX® Vascular Grafts
Study: NCT05392491

Intervention type: OTHER
Intervention: No intervention
Description: No intervention. It is an observational study

Intervention type: OTHER
Intervention: No intervention
Description: No intervention. It is an observational study

Intervention type: OTHER
Intervention: No intervention
Description: No intervention. It is an observational study